This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the recent label expansion of LUMRYZ (sodium oxybate), for the treatment of cataplexy in patients over the age of 7.
Ticker(s): AVDLWho's the expert?
- Board-certified neurologist and sleep physician and a leading voice in sleep medicine,
- Has written more than 1000 articles over the past decade.
- Was a sleep fellow at Stanford University and lectures extensively.
- Treats approximately 25 patients with narcolepsy and cataplexy
Interview Goal to discuss the current treatment landscape and the potential of LUMRYZ (sodium oxybate), an oral therapy recently approved by the FDA for the treatment of cataplexy in patients over the age of 7.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
